Expression and clinical significance of ACSL1 in hepatocellular carcinoma

Abstract

Abstract: Objective To explore the expression of long-chain acyl-CoA synthetase 1 (ACSL1) in hepatocellular carcinoma (HCC) and its clinical values.Methods 334 paired HCC tissues were collected to detect the expression of ACSL1 by immunochemistry staining. The paper also analyzed the relationship between the expression of ACSL1 protein and the clinicopathological characteristics and prognosis of HCC patients. Lentivirus transfection was used to overexpression ACSL1 in HCC cell line SNU739. Cell proliferation and apoptosis were respectively measured by MTS assay and Flow cytometry. Cell energy metabolism were detected by SeahorseXF24 analyer and Lactate Assay Kit.Results The expression of ACSL1 in HCC tissues was markedly lower than that in adjacent tissues (3.02±2.57 vs 7.60±3.34, t=20.040, P=0.000), and the expression of ACSL1 was related to age of the patients (c2 = 16.472, P=0.000). The level of ACSL1 expression was a risk factor for survival in HCC patient (HR=1.642, P=0.012). ACSL1 was significantly promoted cell apoptosis (t=13.886, P=0.000), mitochondrial basal oxygen consumption rate(F=83.429, P=0.001) and maximal oxygen consumption rate(F=859.792, P=0.000)in SNU739 cell.Conclusion ACSL1 is low experssion in HCC tissues, and the prognosis of HCC patient with low ACSL1 expression is worse. ACSL1 can be used as a potential marker of prognosis in HCC patients, which is expected to be helpful to screen for early HCC and improve the survival rate of HCC patients.

Key words: Long-chain acyl-CoA synthetase 1, Hepatocellular carcinoma, Lentivirus transfection, Cell apoptosis, Cell energy metabolism, Prognosis

LI Jiao-jiao, SHI Dou-dou, HUANG Qi-chao, TAO Mei. Expression and clinical significance of ACSL1 in hepatocellular carcinoma[J]. Chinese Hepatolgy, 2022, 27(1): 81-85.

References

[1] Sung H, Ferlay J, Siegel RL,et al.Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin,2021,71:209-249.
[2] Yang JD, Hainaut P, Gores GJ, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol,2019,16:589-604.
[3] 田亚英,傅念,吴清. 长链脂酰辅酶A合成酶及其调控因素的研究及进展. 医学研究杂志,2018,10:13-15.
[4] Sánchez-Martínez R, Cruz-Gil S, García-Alvarez MS,et al. Complementary ACSL isoforms contribute to a non-Warburg advantageous energetic status characterizing invasive colon cancer cells. Sci Rep,2017,7:11143.
[5] Cruz-Gil S, Sanchez-Martinez R, Gomez de Cedron M,et al. Targeting the lipid metabolic axis ACSL/SCD in colorectal cancer progression by therapeutic miRNAs: miR-19b-1 role. J Lipid Res,2018,59:14-24.
[6] Guo L, Lu J, Gao J,et al. The function of SNHG7/miR-449a/ACSL1 axis in thyroid cancer. J Cell Biochem,2020,121:4034-4042.
[7] Zhang Q, Zhou W, Yu S,et al. Metabolic reprogramming of ovarian cancer involves ACSL1-mediated metastasis stimulation through upregulated protein myristoylation. Oncogene, 2021,40:97-111.
[8] Dong Z, Wang J, Zhan T,et al. Identification of prognostic risk factors for esophageal adenocarcinoma using bioinformatics analysis. Onco Targets Ther,2018,11:4327-4337.
[9] Zhou L, Wang Z, Hu C,et al. Integrated Metabolomics and Lipidomics Analyses Reveal Metabolic Reprogramming in Human Glioma with IDH1 Mutation. J Proteome Res, 2019,18:960-969.
[10] Cui M, Xiao Z, Wang Y, et al. Long noncoding RNA HULC modulates abnormal lipid metabolism in hepatoma cells through an miR-9-mediated RXRA signaling pathway. Cancer Res, 2015,75:846-857.
[11] Muir K, Hazim A, He Y,et al. Proteomic and lipidomic signatures of lipid metabolism in NASH-associated hepatocellular carcinoma. Cancer Res,2013,73:4722-4731.
[12] Washington MK, Goldberg RM, Chang GJ, et al. Diagnosis of digestive system tumours. Int J Cancer,2021,148:1040-1050.
[13] Huh JY, Reilly SM, Abu-Odeh M, et al. TANK-Binding Kinase 1 Regulates the Localization of Acyl-CoA Synthetase ACSL1 to Control Hepatic Fatty Acid Oxidation. Cell Metab, 2020,32:1012-1027.e7.
[14] Yang L, Yang Y, Si D, et al. High expression of long chain acyl-coenzyme A synthetase 1 in peripheral blood may be a molecular marker for assessing the risk of acute myocardial infarction. Exp Ther Med,2017,14:4065-4072.
[15] Li LJ, Ma J, Li SB, et al. Vascular endothelial growth factor B inhibits lipid accumulation in C2C12 myotubes incubated with fatty acids. Growth Factors,2019,37:76-84.
[16] Mochizuki K, Yamada M, Inoue T, et al. Bromodomain-containing protein 4 regulates a cascade of lipid-accumulation-related genes at the transcriptional level in the 3T3-L1 white adipocyte-like cell line. Eur J Pharmacol,2020,883:173351.
[17] Li LO, Ellis JM, Paich HA,et al. Liver-specific loss of long chain acyl-CoA synthetase-1 decreases triacylglycerol synthesis and beta-oxidation and alters phospholipid fatty acid composition. J Biol Chem,2009,284:27816-27826.
[18] Li T, Li X, Meng H, et al. ACSL1 affects Triglyceride Levels through the PPARγ Pathway. Int J Med Sci,2020,17:720-727.
[19] Chen WC, Wang CY, Hung YH, et al. Systematic Analysis of Gene Expression Alterations and Clinical Outcomes for Long-Chain Acyl-Coenzyme A Synthetase Family in Cancer. PLoS One,2016,11:e0155660.
[20] Cassim S, Raymond VA, Dehbidi-Assadzadeh L, et al. Metabolic reprogramming enables hepatocarcinoma cells to efficiently adapt and survive to a nutrient-restricted microenvironment. Cell Cycle,2018,17:903-916.
[21] Huang D, Li T, Li X, et al.HIF-1-mediated suppression of acyl-CoA dehydrogenases and fatty acid oxidation is critical for cancer progression. Cell Rep,2014,8:1930-1942.
[22] Nakagawa H, Hayata Y, Kawamura S, et al. Lipid Metabolic Reprogramming in Hepatocellular Carcinoma.Cancers(Basel),2018,10:447.